Goldman Sachs Maintains Neutral on GoodRx Holdings, Lowers Price Target to $5

Benzinga · 4d ago
Goldman Sachs analyst Eric Sheridan maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and lowers the price target from $6 to $5.